Molecular therapy for Myocardial Infarction: BMB2 (Bone morphogenetic protein 2) improves myocardial function after myocardial infarction via up-regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 27/October/2016, 12.29 pm

Natural product-based PD-1 pathway blockade for Human cancer therapy: Isorhapontigenin, isolated from Aiphanes Aculeata, Norway/Sitka/White Spruce, inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 27/october/2016, 8.18 am
October 27, 2016
Natural product-based Combination therapy for Lifespan extension: Green tea extract and Curcumin combo increases life span via up-regulation of its target gene BubR1, 27/October/2016, 2.54 pm
October 27, 2016
Show all

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March  2013 issue of Nature  by Prof Dimmler, Boon, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Myocardial Infarction:  BMB2 (Bone morphogenetic protein 2) improves myocardial function after myocardial infarction via  up-regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10)


Significance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find: (i)  a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free drug.


Research Findings: 

This study suggests a small molecule-based cardiac regeneration therapy. BMP2 (Bone morphogenetic protein 2), by  decreasing the expression of its target gene, it may increase the expression of PNUTS/PPP1R10. Thereby, it may: (1) inhibit DNA damage responses, (2) inhibit telomere shortening; and (3) promote cardiomyocyte survival/regeneration.

Thus, by treating myocardial patients with activators of Nurr1, one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that pharmacological formulations encompassing “BMP2 activators” may be used to improve cardiac function after myocardial infarction.  


Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web:http://genomediscovery.org or http://newbioideas.com

To citeBoominathan, Molecular therapy for Myocardial Infarction:  BMB2 (Bone morphogenetic protein 2) improves myocardial function after myocardial infarction via  up-regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 27/October/2016, 12.29 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org


Undisclosed information: How BMP2 increases the expression of PNUTS/PPP1R10

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $300#

Results guaranteed if not refunded

# Research cooperation

Comments are closed.